COPD: smoking cessation, pulmonary rehab, and the AU primary-care framework

What COPD actually is

The story usually starts the same way. The climb up the driveway that used to be nothing has been getting harder for a couple of years. The flight of stairs at work needs a pause at the landing. Carrying the groceries from the car to the kitchen leaves you breathing harder than feels reasonable. And for a while you tell yourself the obvious thing — I’m just getting older — until the day it becomes harder to ignore. Maybe a chest infection takes three weeks to shift. Maybe a family member says something. Maybe the breathlessness wakes you at night.

Chronic obstructive pulmonary disease (COPD) is a chronic, largely irreversible narrowing of the airways combined with damage to the small air sacs (alveoli) where gas exchange happens. The diagnostic anchor in Australian general practice is a post-bronchodilator FEV1/FVC ratio below 0.7 on spirometry — meaning that after a puff of salbutamol, you cannot empty enough air out of your lungs in the first second relative to the total amount you can blow out. The cause in Australia is overwhelmingly long-term tobacco smoke exposure, though biomass smoke, occupational dust, and genetic factors (alpha-1 antitrypsin deficiency) contribute in a minority.

About 1 in 13 Australian adults over 40 has COPD, rising to roughly 30% in those over 75 with a smoking history (AIHW). And the part of the statistic that matters most clinically: around half are undiagnosed, because the breathlessness comes on slowly enough that the brain re-frames it as ageing. By the time someone presents, FEV1 has often fallen 30–40% from where it would have been. COPD is the third leading cause of death in AU.

A. Core clinical — the AU primary-care framework

Australian general-practice management of COPD runs on the Lung Foundation Australia COPD-X Plan (v2.78, October 2025) — a living guideline from the Thoracic Society of Australia and New Zealand and Lung Foundation Australia. The framework is:

• C — Confirm diagnosis (spirometry)
• O — Optimise function (smoking cessation, vaccination, pulmonary rehab, bronchodilators)
• P — Prevent deterioration (stepwise inhaler therapy)
• D — Develop self-management plan (written COPD Action Plan)
• X — manage eXacerbations (when symptoms flare)

The symptoms worth naming

• Chronic productive cough — often dismissed as “smoker’s cough.” Worth taking seriously, especially if persistent for 3+ months in 2 consecutive years (the older “chronic bronchitis” criterion).
• Breathlessness on exertion — the cardinal symptom. Initially on heavy effort, then walking up hills, then walking on the flat with peers, then stopping to catch breath after 100 metres, then breathless on dressing.
• Wheeze — particularly during exacerbations or on exertion.
• Exercise tolerance decline — gradual, often missed.
• Recurrent chest infections — bronchitis, pneumonia.

How GPs measure severity

The COPD-X plan uses three complementary tools:

Spirometry (MBS item 11506) — measured before and after a bronchodilator. FEV1 as a percentage of predicted defines severity:

Stage	FEV1 % predicted
Mild	≥80%
Moderate	50–79%
Severe	30–49%
Very severe	<30%

Modified MRC dyspnoea scale (mMRC) — 0 (breathless on strenuous exercise only) to 4 (too breathless to leave the house).

COPD Assessment Test (CAT) — an 8-item patient-reported questionnaire scored 0 to 40; ≥10 indicates significant symptom impact.

Exacerbation history in the past 12 months — how many moderate (needing antibiotics or oral steroids) or severe (needing hospitalisation) flare-ups — drives the decision about adding inhaled corticosteroids and is now central to the GOLD ABE assessment used internationally and increasingly in AU practice.

Asthma-COPD overlap (ACO)

A significant minority — particularly former smokers with childhood asthma history — have features of both diseases. Reversibility on spirometry (≥12% and ≥200 mL FEV1 increase post-bronchodilator) does not exclude COPD if FEV1/FVC remains <0.7, but it does raise the consideration. ACO matters because it changes inhaler choice — ICS is more central in ACO than in pure COPD.

Other tests worth doing

CXR (exclude alternatives — lung cancer, heart failure, pneumothorax). FBC — eosinophil count predicts ICS responsiveness; haemoglobin (anaemia worsens dyspnoea). Pulse oximetry at rest and on exertion. BMI and nutritional assessment (under 21 is a mortality marker). Alpha-1 antitrypsin level if onset before age 45, never-smoker, or strong family history.

B. Evidence appraisal — pharmacotherapy stepwise

Per the COPD-X v2.78, inhaler therapy steps up based on symptom burden and exacerbation history.

Step 1 — SABA only

Short-acting beta-2 agonist (salbutamol) via spacer, used as needed for breathlessness. Appropriate in genuinely mild, intermittent disease — though most people with confirmed COPD warrant a long-acting agent.

Step 2 — single long-acting bronchodilator

LAMA (long-acting muscarinic antagonist) or LABA (long-acting beta-2 agonist). Both classes work well as monotherapy; LAMAs have a slight edge on exacerbation reduction.

LAMAs available on PBS for COPD via Authority Required (Streamlined):

• Tiotropium (Spiriva) 18 mcg once daily
• Umeclidinium (Incruse Ellipta) 62.5 mcg once daily
• Glycopyrronium (Seebri Breezhaler) 50 mcg once daily
• Aclidinium (Bretaris) 322 mcg twice daily

LABAs available on PBS:

• Indacaterol (Onbrez) 150–300 mcg once daily
• Olodaterol (component of Spiolto)
• Salmeterol 50 mcg twice daily
• Formoterol 12 mcg twice daily

Step 3 — dual LAMA+LABA

Multiple AU-listed combination inhalers, taken as preferred over either class alone for persistent symptoms on monotherapy (FLAME NEJM 2016):

Brand	Composition
Anoro Ellipta	Umeclidinium + vilanterol
Spiolto Respimat	Tiotropium + olodaterol
Ultibro Breezhaler	Glycopyrronium + indacaterol

Step 4 — triple therapy (LAMA+LABA+ICS)

COPD-X v2.78 is explicit about when to add inhaled corticosteroids. Triple therapy is indicated for patients with:

• ≥1 severe exacerbation requiring hospitalisation, OR ≥2 moderate exacerbations in the past 12 months, despite optimised dual bronchodilator therapy.
• Eosinophilic phenotype (blood eosinophils ≥300 cells/µL) — predicts better ICS response.
• Asthma-COPD overlap.

The trials behind this — IMPACT (NEJM 2018) and ETHOS (NEJM 2020) — showed reduced exacerbation rates with triple therapy, and ETHOS also showed a mortality signal in the high-dose ICS arm.

AU triple-therapy inhalers (PBS Authority Required, Streamlined):

• Trelegy Ellipta (umeclidinium + vilanterol + fluticasone furoate)
• Trimbow MDI (glycopyrronium + formoterol + beclomethasone)
• Breztri Aerosphere (glycopyrronium + formoterol + budesonide)

The honest counter-point: ICS in COPD increases pneumonia risk approximately 1.6-fold (Suissa Thorax 2013). For someone with low exacerbation rates and eosinophils under 100, ICS adds risk without benefit. The COPD-X plan recommends considering an ICS withdrawal trial in patients on triple therapy for ≥12 months with no exacerbations and eosinophils <100. This is a worthwhile conversation to have with your GP if it applies.

Beyond inhalers — for the frequent exacerbator

Roflumilast 500 mcg daily — a PDE4 inhibitor for severe COPD with chronic bronchitis phenotype and FEV1 <50% (REACT Lancet 2015). PBS Authority. GI side effects (nausea, weight loss, diarrhoea) are common.

Azithromycin prophylaxis 250 mg three times weekly — reduces exacerbations by about 27% in frequent exacerbators (Albert NEJM 2011). Specialist-initiated, with baseline ECG (QT interval), audiometry (hearing loss risk), and ongoing surveillance.

Biologics (mepolizumab, dupilumab) — emerging in highly selected eosinophilic phenotypes; PBS criteria are evolving and specialist-only.

Oxygen therapy

Long-term oxygen therapy (LTOT) for at least 15 hours per day extends life in severe resting hypoxaemia (NOTT 1980, MRC 1981). AU criteria:

• PaO2 ≤55 mmHg on a stable day, OR
• PaO2 56–59 mmHg with cor pulmonale, polycythaemia (HCT >55%), or pulmonary hypertension.

Assessed by a respiratory physician with an arterial blood gas. Funded through state schemes — VAOTP (Vic), EnableNSW, MASS (Qld). Ambulatory oxygen for moderate exertional desaturation without resting hypoxaemia did not improve mortality or quality of life in the LOTT trial (NEJM 2016) — so it is not routinely recommended.

When OSA overlaps with COPD

Around 10–15% of COPD patients have coexistent obstructive sleep apnoea — “overlap syndrome.” Symptoms of disordered sleep, daytime hypersomnolence, witnessed apnoeas, and worsening morning headaches warrant a sleep study. Treating OSA with CPAP (or BiPAP if hypercapnic) in overlap-syndrome patients reduces mortality and hospitalisations independently of COPD management.

C. Non-pharmacological — the disease-modifying interventions

Inhalers open the airways. Smoking cessation and pulmonary rehabilitation change the disease.

Smoking cessation — the single most powerful intervention

The Lung Health Study (Anthonisen et al., the seminal 14-year cohort) showed that smokers who quit had a rate of FEV1 decline approaching the normal age-related rate of around 25 mL/year, while continuing smokers lost FEV1 at roughly double that rate. Nothing else in COPD management changes the trajectory in this way. The framing is honest: smoking cessation does not undo damage, but it prepares the environment so the body slows the loss to age-related rates.

The AU primary tier (RACGP supporting smoking cessation guideline) recommends a combined approach:

• Quitline AU on 13 7848 — behavioural counselling, free, multiple call-back sessions; effective at quit rates well above unaided attempts.
• Varenicline (Champix) 0.5 mg titrating to 1 mg twice daily for 12 weeks. PBS-listed for smoking cessation. Strongest single agent.
• Nicotine replacement therapy — combination of patch (long-acting baseline) plus a short-acting form (gum, lozenge, inhalator, oral spray) for cravings. PBS-listed for eligible smokers via Authority.
• Bupropion (Zyban) 150 mg titrating to 300 mg daily — alternative to varenicline; PBS-listed.

Combined pharmacotherapy plus counselling produces quit rates roughly three times higher than unaided attempts. Vaping is not a recommended cessation aid in AU; the TGA and RACGP position is to use TGA-listed cessation pharmacotherapy instead.

Pulmonary rehabilitation

A structured 8-week program of supervised exercise, breathing techniques, and education delivered by physiotherapists and exercise physiologists. The Cochrane meta-analysis (McCarthy 2015) showed reduced hospitalisations of around 39%, improved dyspnoea, and improved quality of life. The mortality signal in repeated meta-analyses is consistent with benefit.

Lung Foundation Australia maintains a directory of accredited programs through public hospitals and community health services. Referral via GP under a Chronic Disease Management plan (see Section D) with allied health items attached. The COPD-X plan recommends referral for all symptomatic or exacerbation-prone COPD patients — not just those with severe disease. If standard PR is unavailable or declined, tai chi has shown comparable effects in some trials.

Vaccination

Per the Australian Immunisation Handbook, recommended for adults with COPD:

• Annual influenza vaccine — funded under the NIP for chronic disease patients.
• Pneumococcal — current ATAGI advice favours a single dose of Prevenar 20 in adults with COPD, replacing the older Prevenar 13 + Pneumovax 23 sequence in most cases. Worth confirming current schedule with your GP.
• COVID-19 — boosters per current ATAGI guidance.
• RSV adult vaccine — recommended for adults ≥75, and for those 60–74 with high-risk conditions including COPD (added to AU schedule 2024).
• Pertussis — 10-yearly booster, particularly relevant for grandparents or household contacts of newborns.

Exercise, nutrition, mental health

Outside of formal pulmonary rehab, day-to-day physical activity — regular walking, resistance training, household work — matters. The mechanism is the same as for PR: building peripheral muscle capacity that has often deconditioned from years of breathlessness avoidance.

Nutrition cuts both ways. BMI under 21 in COPD is an independent mortality marker — cachexia from chronic inflammatory disease, increased work of breathing, and reduced intake. Conversely, obesity worsens breathlessness and exercise tolerance. Both warrant dietitian input via the Chronic Disease Management plan.

Around 40% of people with COPD have clinically significant depression or anxiety — both as a response to the loss of function and as part of the systemic inflammatory picture. Worth screening for actively; treatment improves both mental and respiratory outcomes.

The COPD Action Plan

A written, personalised, traffic-light plan — green (well), yellow (worse), red (urgent) — with specific instructions for what to do when symptoms shift. Templates available from Lung Foundation Australia. The yellow zone usually includes increased reliever use plus starting a stand-by course of oral prednisolone 30–50 mg daily for 5 days (REDUCE JAMA 2013 showed 5 days is non-inferior to 14), plus an antibiotic if sputum becomes more purulent (Anthonisen criteria: increased dyspnoea, sputum volume, sputum purulence — ≥2 of 3 triggers antibiotic use, typically amoxicillin 500 mg TDS or doxycycline 100 mg BD for 5 days per eTG).

D. Australian operations

MBS items worth knowing

• Standard GP consults — 3 / 23 / 36 / 44.
• Pre/post bronchodilator spirometry — item 11506 — general-practice rebatable.
• Chest X-ray — item 58503.
• GP Chronic Conditions Management Plan (GPCCMP) — 965 / 967. COPD qualifies as a chronic condition >6 months, so a structured plan is appropriate.
• Allied health under the GPCCMP/TCA framework — 10960 and related items; up to 5 visits per calendar year across physiotherapy, exercise physiology, dietitian, and others.
• Mental Health Care Plan — 2715 / 2717 — for the ~40% with comorbid depression or anxiety, via Better Access (10 subsidised psychology sessions/year).
• Practice nurse review of COPD action plan — item 10997.
• Aboriginal and Torres Strait Islander Health Assessment — item 715.
• 6-minute walk test — item 11503 (typically pulmonary rehab / specialist context).

(MBS / PBS items verified 2026-05-18 via WebSearch — workspace egress to mbsonline.gov.au and pbs.gov.au currently blocked; spot-check confirms current.)

PBS — inhaler authority requirements

Most COPD-relevant inhalers are PBS Authority Required (Streamlined) — meaning a streamlined authority code is included on the script rather than a phone call to Services Australia. The categories:

• SABA/SAMA (salbutamol, ipratropium) — general schedule.
• LAMA monotherapy, LABA monotherapy, LAMA+LABA combinations — Authority Required (Streamlined) for COPD.
• LAMA+LABA+ICS triple combinations (Trelegy Ellipta, Trimbow, Breztri Aerosphere) — Authority Required (Streamlined) for COPD with documented prior exacerbations.
• Roflumilast — Authority Required for severe COPD with chronic bronchitis phenotype, FEV1 <50%.
• Smoking cessation — varenicline, NRT, and bupropion are PBS-listed via the smoking cessation listings.

Pulmonary rehab and home oxygen

Pulmonary rehab is funded primarily through state-based outpatient programs at public hospitals and community health services, plus private programs accessible via the GPCCMP allied health items. The Lung Foundation Australia program directory lists local options.

Home oxygen funding sits outside PBS — state schemes administer eligibility and supply: VAOTP in Victoria, EnableNSW in NSW, MASS in Queensland, equivalents in other states. Eligibility assessed by a respiratory physician per Thoracic Society of Australia and New Zealand criteria.

E. Special populations

Aboriginal and Torres Strait Islander adults carry a disproportionate burden — higher prevalence, younger age of onset, more severe disease at diagnosis. Contributors include higher smoking rates, biomass and household smoke exposure, and overcrowding. The Lung Foundation Australia runs ATSI-specific COPD programs, and the ATSI Health Assessment (MBS 715) is the entry point in general practice.

Older adults — inhaler technique declines with age, often unrecognised. Hand strength, coordination, and inspiratory flow all matter. Soft-mist inhalers (Respimat) and dry-powder inhalers with low inspiratory resistance suit different patients. Spacers improve MDI deposition substantially. The practice nurse review under MBS 10997 is a useful checkpoint.

End-stage palliative integration. COPD has a less predictable trajectory than many cancers, and palliative care is often introduced too late. Anticipatory prescribing — low-dose oral opioid (morphine 1–2 mg) for refractory breathlessness, with appropriate consent and titration — is supported by AU palliative care guidelines. Advance care planning and discussions about CPR, intubation preferences, and goals-of-care should happen in the stable phase, not in the ED at 2am.

When to escalate / respiratory referral

• Diagnostic uncertainty — asthma vs COPD vs bronchiectasis vs pulmonary fibrosis vs cardiac dyspnoea.
• Frequent exacerbations despite optimised inhaler therapy and pulmonary rehab.
• Severe disease (FEV1 <50%) — for specialist co-management.
• Suspected alpha-1 antitrypsin deficiency — onset <45y, never-smoker, basal-predominant emphysema on CT, strong family history.
• Oxygen assessment — for arterial blood gas and LTOT eligibility.
• Lung volume reduction or transplant assessment — selected upper-lobe-predominant emphysema, FEV1 <30%.
• Palliative integration when symptom burden is high despite optimised therapy.

Urgent escalation (ED) for: severe exacerbation with hypoxaemia, drowsiness, confusion, suspected pneumothorax, suspected pulmonary embolism (COPD exacerbation with no clear infective trigger), or new haemoptysis with weight loss (lung cancer is more common in COPD smokers).

What this article is and is not

This is general health information drawn from current Australian primary-care guidelines — the Lung Foundation Australia COPD-X plan, Therapeutic Guidelines, Australian Medicines Handbook, NPS MedicineWise, the Australian Immunisation Handbook, the RACGP smoking cessation guideline — and the major COPD trials. It is not personal medical advice and does not create a doctor–patient relationship. Decisions about inhaler choice, oxygen therapy, smoking cessation pharmacotherapy, and other specific treatments are made with your own GP and treating clinicians.

For Australian consumer resources: Lung Foundation Australia, HealthDirect — COPD, Better Health Channel, Quitline Australia on 13 7848.

---

Sources cited

1. Lung Foundation Australia / TSANZ — COPD-X Plan v2.78 (October 2025)
2. Lung Foundation Australia — COPD-X Handbook 2025
3. Lung Foundation Australia — COPD consumer information
4. Lung Foundation Australia — Pulmonary rehabilitation directory
5. RACGP — Supporting smoking cessation guideline
6. Therapeutic Guidelines (eTG) — Respiratory: COPD
7. Australian Medicines Handbook
8. NPS MedicineWise
9. Australian Immunisation Handbook
10. HealthDirect — COPD
11. Better Health Channel — COPD
12. AIHW — COPD report
13. Quitline Australia (13 7848)
14. TGA
15. PBS
16. MBS item 11506 — spirometry
17. MBS item 58503 — chest X-ray
18. MBS item 11503 — 6-minute walk test
19. MBS items 965 / 967 — GP Chronic Conditions Management Plan
20. MBS item 10960 — allied health under TCA
21. MBS items 2715 / 2717 — Mental Health Care Plan
22. MBS item 10997 — practice nurse review
23. MBS item 715 — ATSI Health Assessment
24. MBS item 65070 — FBC
25. McCarthy et al. — Pulmonary rehabilitation for COPD (Cochrane 2015)
26. Lipson et al. — Triple therapy in COPD (IMPACT, NEJM 2018)
27. Rabe et al. — Triple therapy in COPD (ETHOS, NEJM 2020)
28. Suissa et al. — ICS and pneumonia risk in COPD (Thorax 2013)
29. Wedzicha et al. — LABA-LAMA vs LABA-ICS (FLAME, NEJM 2016)
30. Albert et al. — Azithromycin prophylaxis (NEJM 2011)
31. Leuppi et al. — REDUCE: 5 vs 14 day steroids for exacerbations (JAMA 2013)
32. Long-Term Oxygen Treatment Trial — LOTT (NEJM 2016)
33. NOTT — Continuous vs nocturnal oxygen (Ann Intern Med 1980)
34. MRC — Long-term oxygen therapy (Lancet 1981)
35. Martinez et al. — Roflumilast in severe COPD (REACT, Lancet 2015)
36. Polkey et al. — Tai chi vs pulmonary rehabilitation (CHEST 2018)